Recently, the recombinant zoster vaccine has officially become available in Beijing for a newly approved indication. Previously authorized for individuals aged 50 and older to prevent shingles, the vaccine’s indication has now been expanded to include adults aged 18 and above who have specific high-risk factors—such as immunocompromised conditions or chronic illnesses like diabetes and chronic kidney disease. This expansion is supported by recent clinical trial data demonstrating the vaccine’s strong safety profile and immunogenicity in this broader population.Shingles is a painful rash caused by the reactivation of the varicella-zoster virus, commonly affecting older adults. However, incidence rates among younger, high-risk individuals have been rising in recent years. Vaccination remains the most effective preventive measure. As one of the first pilot cities in China, Beijing now offers the vaccine at multiple community health centers and designated medical institutions.Health experts recommend that eligible individuals consult their physicians promptly and complete the two-dose vaccination schedule to ensure optimal protection. This proactive step not only safeguards personal health but also helps reduce the overall healthcare burden and enhances public health outcomes.
近日，重组带状疱疹疫苗在北京正式开启针对新适应症的接种服务。该疫苗此前已获批用于50岁及以上人群预防带状疱疹，而此次扩展的新适应症将适用年龄下探至18岁及以上、具有特定高风险因素的成年人群，如免疫功能低下者或患有慢性疾病（如糖尿病、慢性肾病等）的人士。这一调整基于最新的临床研究数据，证实该疫苗在更广泛人群中具有良好的安全性和免疫原性。带状疱疹是由水痘-带状疱疹病毒再激活引起的一种疼痛性皮疹疾病，常见于中老年人，但近年来在年轻高风险群体中的发病率也呈上升趋势。及时接种疫苗是目前最有效的预防手段。北京作为全国首批试点城市之一，已在多个社区卫生服务中心和指定医疗机构提供该疫苗的接种服务。专家建议，符合新适应症条件的人群应尽早咨询医生并完成两剂次接种，以获得充分保护。此举不仅有助于个体健康，也有助于降低整体医疗负担，提升公共卫生水平。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/5625.html